Coordinated Services and Access to Research for Women, Infants, Children, and Youth

Part D (base): The purpose of this program is to fund family-centered HIV care and support services in outpatient or ambulatory settings to low-income women, infants, children and youth with HIV, and their affected family members. Part D (supple

Part D (base): The purpose of this program is to fund family-centered HIV care and support services in outpatient or ambulatory settings to low-income women, infants, children and youth with HIV, and their affected family members. Part D (supplemental): The purpose of this one-year supplemental funding is to strengthen organizational infrastructure and increase capacity to develop, enhance, or expand access to high quality family-centered care services. These services are for low-income women, infants, children, and youth (WICY) with HIV in the service area.

Eligible applicants are: State (includes District of Columbia, public institutions of higher education and hospitals), Local (includes State-designated Indian Tribes, excludes institutions of higher education and hospitals, Public nonprofit institution/organization (includes institutions of higher education and hospitals), Federally Recognized Indian Tribal Governments, U.S. Territories and possessions, Private nonprofit institution/organization (includes institutions of higher education and hospitals), State Public and nonprofit private entities (including a health facility operated by or pursuant to a contract with the Indian Health Service) that provide family-centered care involving outpatient or ambulatory care (directly or through contracts or memoranda of understanding (MOUs) for WICY with HIV/AIDS.

Specialized group (e.g. health professionals, students, veterans) Women, infants, children, and youth living with HIV and their affected family members.

All funds must be expended solely for carrying out the approved project in accordance with the NOFO, the terms and conditions of the award, and the applicable cost principles. No more than 10 percent of total grant funds may be used for administrative costs. All indirect costs count toward this 10% limit. Funds may not be used for purchase, construction, or major alterations or renovations on any building or other facility; purchase or improvement of land; payments for clinical research; payments for nursing home care; cash payments to intended recipients of RWHAP services; research; foreign travel; to directly provide housing or health care services (e.g., HIV care, counseling and testing) that duplicate existing services; or for any item or service to the extent that payment has been made, or reasonably can be expected to be made, with respect to that item or service under any State compensation program, insurance policy, Federal or State health benefits program or by an entity that provides health services on a prepaid basis (except for a program administered by or providing the services of the Indian Health Services). Funds may also not be used towards PrEP or nPEP medications or medical services. As outlined in the June 22, 2016 RWHAP and PrEP program letter, the RWHAP legislation provides grant funds to be used for the care and treatment of people with HIV, thus prohibiting the use of RWHAP funds for PrEP medications or related medical services, such as physician visits and laboratory costs. However, RWHAP Part D funds can be used toward Psychosocial Support Services, a component of family-centered care, which may include counseling and testing and information on PrEP to eligible clients' partners and affected family members, within the context of a comprehensive PrEP program. Additionally, the purchase of sterile needles or syringes for the purposes of hypodermic injection of any illegal drug is not allowable. Some aspects of Syringe Services Programs are allowable with HRSA's prior approval and in compliance with HHS and HRSA policy (see: https://www.aids.gov/federal-resources/policies/syringe-services-programs/).

All funds must be expended solely for carrying out the approved project in accordance with the NOFO, the terms and conditions of the award, and the applicable cost principles. No more than 10 percent of total grant funds may be used for administrative costs. All indirect costs count toward this 10% limit. Funds may not be used for purchase, construction, or major alterations or renovations on any building or other facility; purchase or improvement of land; payments for clinical research; payments for nursing home care; cash payments to intended recipients of RWHAP services; research; foreign travel; to directly provide housing or health care services (e.g., HIV care, counseling and testing) that duplicate existing services; or for any item or service to the extent that payment has been made, or reasonably can be expected to be made, with respect to that item or service under any State compensation program, insurance policy, Federal or State health benefits program or by an entity that provides health services on a prepaid basis (except for a program administered by or providing the services of the Indian Health Services). Funds may also not be used towards PrEP or nPEP medications or medical services. As outlined in the June 22, 2016 RWHAP and PrEP program letter, the RWHAP legislation provides grant funds to be used for the care and treatment of people with HIV, thus prohibiting the use of RWHAP funds for PrEP medications or related medical services, such as physician visits and laboratory costs. However, RWHAP Part D funds can be used toward Psychosocial Support Services, a component of family-centered care, which may include counseling and testing and information on PrEP to eligible clients' partners and affected family members, within the context of a comprehensive PrEP program. Additionally, the purchase of sterile needles or syringes for the purposes of hypodermic injection of any illegal drug is not allowable. Some aspects of Syringe Services Programs are allowable with HRSA's prior approval and in compliance with HHS and HRSA policy (see: https://www.aids.gov/federal-resources/policies/syringe-services-programs/).

Grants are typically awarded for up to a 3 year period of performance. Continued support, beyond the first year, is contingent upon satisfactory performance, the availability of Federal funds, and the continued best interest of the government. Supplemental grants may be funded for up to 1 year. Method of awarding/releasing assistance: Recipients draw down funds, as necessary, from the Payment Management System (PMS). PMS is the centralized web based payment system for HHS awards.

Preapplication coordination is required. Environmental impact information is not required for this program. This program is eligible for coverage under E.O. 12372, "Intergovernmental Review of Federal Programs." An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review. An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review.

Eligible applicants are reviewed by an objective review committee based on the criteria detailed in the NOFO.

Based on the recommendations of the objective review committee, the HRSA program official with delegated authority is responsible for final selection and funding decisions. Notification is made in writing by a Notice of Award (NOA).

Approximately 6 months.